Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 321

Tildrakizumab confirms its long-term efficacy and safety with the longest

Posted by fidest press agency su domenica, 13 ottobre 2019

Almirall, S.A. (ALM) announces the presentation of the results of 14 abstracts about efficacy and safety of long-term tildrakizumab treatment at the 28th EADV Congress by Almirall and SUN Pharma to bring the newest data about psoriasis biological therapies. One of the studies, an open-label extension from baseline reSURFACE 1 a phase III clinical trial and shows that, following up to 4 years of treatment with tildrakizumab 100 mg, PASI and PGA response rates are high and durable.1 An extension study from reSURFACE 1 and reSURFACE 2 phase III clinical trials has also been presented showing that there is no dose-dependent tildrakizumab effect on the incidence of malignancy.2 This is the longest data available on an IL23p19 inhibitor, the most innovative class of drugs for the treatment of moderate-to-severe psoriasis. The third study is a pooled analysis through 3 years also from reSURFACE 1 and 2 phase III clinical trials showing that tildrakizumab was well tolerated with low SAEs and adverse effects of a subpopulation of patients 65 years of age or older. Tildrakizumab is a humanized high-affinity anti-IL23p19 monoclonal antibody approved in Europe under the brand name ILUMETRI® for the treatment of moderate-to-severe plaque psoriasis.3 Due to its specific mechanism of action, it selectively blocks interleukin-23 (IL-23), a key regulatory cytokine, essential in T-helper 17 cell differentiation and survival, which are the cells instrumental in the pathogenesis of psoriasis.

Rispondi

Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di WordPress.com

Stai commentando usando il tuo account WordPress.com. Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

 
%d blogger hanno fatto clic su Mi Piace per questo: